Literature DB >> 1223721

Studies on phospholipids in the action of a lupus coagulation inhibitor.

T Exner, K A Rickard, H Kronenberg.   

Abstract

Plasma from a patient with early manifestations of disseminated lupus erythematosus, a prolonged partial thromboplastin time with kaolin, mildly prolonged prothrombin time, and a circulating inhibitor affecting the assay of several clotting factors was investigated. The most sensitive test for the inhibitor was found to be the Russell viper venom time without phospholipid. A decrease in phospholipid concentration as well as decreased sodium chloride levels both significantly enhanced the effect of the inhibitor in several coagulation tests. Of various phospholipid substitutes tested phosphatidyl ethanolamine was the most effective in partially correcting for the inhibitor. The inhibitor was not localized to the patient's platelets, which were also found to partially neutralize its effect. Since lupus erythematosus is sometimes accompanied by thrombocytopenia the coagulation disorder may be aggravated by such a deficiency of phospholipid. The inhibitor appears to act by preventing binding of phospholipid to the Xa/V/thromboplastin complex. It was characterized as a gamma globulin of mixed class.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1223721     DOI: 10.3109/00313027509081688

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  11 in total

Review 1.  Detection of lupus anticoagulants.

Authors:  M H Horellou; M M Samama
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

2.  Circulating lupus type anticoagulant and pulmonary hypertension associated with mixed connective tissue disease.

Authors:  P Hainaut; E Lavenne; J M Magy; E G Lebacq
Journal:  Clin Rheumatol       Date:  1986-01       Impact factor: 2.980

3.  Phospholipid in the hexagonal II phase is immunogenic: evidence for immunorecognition of nonbilayer lipid phases in vivo.

Authors:  J Rauch; A S Janoff
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

4.  Budd-Chiari syndrome as the major thrombotic complication of systemic lupus erythematosus with the lupus anticoagulant.

Authors:  M Averbuch; Y Levo
Journal:  Ann Rheum Dis       Date:  1986-05       Impact factor: 19.103

5.  Multiple thromboses in systemic lupus erythematosus.

Authors:  S Appan; M L Boey; K W Lim
Journal:  Arch Dis Child       Date:  1987-07       Impact factor: 3.791

Review 6.  Immunologically generated circulating anticoagulants in humans.

Authors:  R L Edwards; C J Wakem
Journal:  Surv Immunol Res       Date:  1984

7.  Cardiac disease in systemic lupus erythematosus: prospective study of 70 patients.

Authors:  R Cervera; J Font; C Paré; M Azqueta; F Pérez-Villa; A López-Soto; M Ingelmo
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

8.  The lupus anticoagulant, pulmonary thromboembolism, and fatal pulmonary hypertension.

Authors:  N E Anderson; M R Ali
Journal:  Ann Rheum Dis       Date:  1984-10       Impact factor: 19.103

9.  Systemic lupus erythematosus in the elderly: clinical and immunological characteristics.

Authors:  J Font; L Pallarés; R Cervera; A López-Soto; M Navarro; X Bosch; M Ingelmo
Journal:  Ann Rheum Dis       Date:  1991-10       Impact factor: 19.103

10.  Systemic lupus erythematosus in 50 year olds.

Authors:  I Domenech; O Aydintug; R Cervera; M Khamashta; A Jedryka-Goral; J L Vianna; G R Hughes
Journal:  Postgrad Med J       Date:  1992-06       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.